What are the challenges and limitations of VEGF-targeted therapies?
While VEGF-targeted therapies have shown efficacy in treating various cancers, there are several challenges and limitations. These include:
Resistance: Tumors can develop resistance to VEGF inhibitors through various mechanisms, such as the upregulation of alternative angiogenic pathways. Side effects: Anti-VEGF therapies can cause significant side effects, including hypertension, proteinuria, and impaired wound healing. Heterogeneity: Tumor heterogeneity can lead to variable responses to VEGF-targeted therapies, making it difficult to predict treatment outcomes.
